Jessica Hergert
Articles
Updated NCCN Guidelines Now Include Neratinib for HER2+ Breast Cancer
January 27, 2022
Article
The update is in agreement with the FDA approval of a labeling supplement in June 2021 to the United States Prescribing Information for neratinib in HER2-positive breast cancer.
Patients With Biliary Tract Cancers Benefit From Durvalumab Plus Chemotherapy
January 20, 2022
Article
Checkpoint inhibitors may have clinical utility in BTC based on immunogenic features of the disease; however, limited clinical activity has been observed with single-agent therapy in the advanced setting.
Immunotherapy Approvals Propel the Future of GI Cancer Treatment
January 05, 2022
Article
Event co-chair, Syma Iqbal, MD, discusses key points from a recent OncLive® Institutional Perspectives in Cancer webinar, which focused on the evolving landscapes in gastrointestinal cancer.
New ESMO Breast Cancer Guidelines Emphasize Personalized Treatment, Multidisciplinary Decision Making
November 14, 2021
Article
Nuanced and multidisciplinary decision making are needed to optimize and personalize locoregional, systemic, and supportive care in metastatic breast cancer.
Personalized Medicine May Help Alleviate Certain Health Disparities in Cancer Care
November 12, 2021
Article
The COVID-19 pandemic has demonstrated that personalized medicine should consider social determinants of health disparities as well as genomic factors.
Relationship Between MSH2, MSH6 and Prostate Cancer Incidence Highlights Value of PSA Screenings
November 04, 2021
Article
The increased risk of prostate cancer associated with MSH2 and MSH6 pathogenic variants point to a need for annual PSA screening in men over the age of 40.
CAR T-Cell Therapy Recipients May Require Specialized COVID-19 Vaccine Strategies
November 03, 2021
Article
CAR T-cell therapies represent a potent treatment option for patients with heavily pretreated relapsed/refractory hematologic malignancies, however, the infection risk associated with treatment may hinder the efficacy of COVID-19 vaccines in this population.
New Drug Approvals Expand cGVHD Treatment Beyond Steroids, But Real-World Data Still Needed
October 30, 2021
Article
Ruxolitinib and belumosudil represent FDA-approved treatment options to manage cGVHD, however, real world data will determine best practices for treatment and future research directions within the space.
Careful Patient Monitoring Critical in Emerging Lung Cancer Treatments
October 28, 2021
Article
Antoinette Wozniak, MD, FACP, FASCO, outlines the importance of careful patient monitoring in lung cancer and emerging therapy options expected to change the treatment landscape.
New Clinical Trial Will Assess Novel ADC in Drug Resistant HER2+ Breast Cancer
October 23, 2021
Article
The recently launched phase 2 ACE-Breast03 seeks to appraise the efficacy and safety of the novel antibody-drug conjugate, ARX788, in patients with metastatic HER2-positive breast cancer whose disease is resistant to previous targeted therapies.